全身11C-乙酸盐PET/CT对惰性或低侵袭性淋巴瘤的肿瘤识别
该前瞻性研究纳入17例病理证实的低侵袭性或惰性淋巴瘤患者,同日行18F-FDG PET/CT与11C-乙酸盐PET/CT,比较全身病灶检出。11C-乙酸盐PET/CT检出的淋巴结及结外病灶区域数均显著多于18F-FDG PET/CT,提示其对这类淋巴瘤病灶检测敏感性更高。
要点
- 11C-乙酸盐PET/CT检出淋巴结病灶区域84个,显著多于18F-FDG的64个(P<0.001)。
- 结外病灶检出26个区域,显著多于18F-FDG的19个(P=0.039)。
- 骨 marrow 受累灵敏度:11C-乙酸盐100%(6/6),18F-FDG 80%(5/6)。
核心结论
- 11C-乙酸盐PET/CT对低侵袭性或惰性淋巴瘤的病灶检测敏感性高于18F-FDG PET/CT。
研究设计与样本
- 前瞻性研究,2016年9月至2018年5月纳入17例病理证实的低侵袭性或惰性淋巴瘤患者(9男8女,平均年龄71岁,范围45-87岁)。
- 所有患者同日行18F-FDG PET/CT与11C-乙酸盐PET/CT,按Ann Arbor分类记录淋巴结病灶并评估结外病灶。
- 采用McNemar检验比较两种示踪剂的全身病灶检出。
主要发现
- 11C-乙酸盐PET/CT检出淋巴结病灶区域84个,18F-FDG检出64个,差异显著(P<0.001)。
- 11C-乙酸盐PET/CT检出结外病灶区域26个,18F-FDG检出19个(P=0.039)。
- 骨病灶在11C-乙酸盐PET/CT和18F-FDG PET/CT分别于8例和5例患者中检出(P=0.25)。
- 14例(82.4%)患者行骨髓活检,11C-乙酸盐PET/CT和18F-FDG PET/CT检测骨髓受累的灵敏度分别为100%(6/6)和80%(5/6)。
- 1例患者脾脏多发局灶性摄取仅见于18F-FDG PET/CT,11C-乙酸盐PET/CT未见。
临床怎么用
- 对18F-FDG PET/CT怀疑低侵袭性或惰性淋巴瘤病灶检测不足时,可考虑补充11C-乙酸盐PET/CT评估。
局限性
- 样本量小(17例),为单中心前瞻性研究。
- 骨病灶检出差异无统计学意义(P=0.25)。
- 骨髓受累灵敏度基于14例行骨髓活检的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to investigate the diagnostic performance of whole-body [C]acetate PET/CT in less aggressive or indolent lymphomas, wherein [F]FDG PET/CT would exhibit limited sensitivity. METHODS: Between September 2016 and May 2018, we prospectively evaluated 17 patients (9 men, 8 women; mean age [range], 71 [45-87] years) with pathologically proven less aggressive or indolent lymphomas according to Non-Hodgkin's Lymphoma Classification Project, using both [F]FDG PET/CT and [C]acetate PET/CT (performed on the same day). Detected nodal lesions were recorded according to the Ann Arbor classification. Extranodal (EN) lesions were also evaluated. We compared whole-body lesion detection between [F] FDG PET/CT and [C]acetate PET/CT using the McNemar test. RESULTS: In all patients, significantly more nodal and EN lesions were detected using [C]acetate PET/CT than [F]FDG PET/CT (nodal: 84 vs 64 regions; P < 0.001; EN: 26 vs 19 regions, P = 0.039). Bone lesions were detected in 8 and 5 patients using [C]acetate PET/CT and [F]FDG PET/CT, respectively (P = 0.25). Among the 14 patients (82.4%) who underwent bone marrow biopsy, bone marrow involvement was detected with sensitivities of 100% (6/6 patients) and 80% (5/6 patients) using [C]acetate PET/CT and [F]FDG PET/CT, respectively. Multiple areas of focal uptake in the spleen of 1 patient were exhibited on [F]FDG PET/CT but not [C]acetate PET/CT. CONCLUSIONS: [C]acetate PET/CT exhibited greater sensitivity than [F]FDG PET/CT for lesion detection in patients with less aggressive or indolent lymphomas, thus promising applicability as a physiological tracer in the study of such lesions.
引用
- Tsuchiya J, Yamamoto M, Bae H, et al. Tumor Identification of Less Aggressive or Indolent Lymphoma With Whole-Body 11C-Acetate PET/CT. Clin Nucl Med. 2019. PMID: 30688736. doi:10.1097/RLU.0000000000002464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。